Current progress in pulmonary delivery of measles vaccine

References

• Lievano F, Galea SA, Thornton M, et al. Measles, mumps, and rubella virus vaccine (M-M-RII): a review of 32 years of clinical and postmarketing experience. Vaccine 2012;30:6918-26
   PubMed Web of Science ®Google Scholar
• Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 2011;204(Suppl 1):S133-48
   PubMedGoogle Scholar
• Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004;189(Suppl 1):S4-16
   PubMedGoogle Scholar
• Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol 2006;4:900-8
   PubMed Web of Science ®Google Scholar
• Parker AA, Staggs W, Dayan GH, et al. Implications of a. 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006;355:447-55
   PubMed Web of Science ®Google Scholar
• Dallaire F, De Serres G, Tremblay FW, et al. Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. J Infect Dis 2009;200:1602-5
   PubMed Web of Science ®Google Scholar
• Gay N. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 2004;189:S27-35
   PubMed Web of Science ®Google Scholar
• Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004;189(Suppl 1):S43-7
   PubMedGoogle Scholar
• Rota JS, Wang ZD, Rota PA, Bellini WJ. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 1994;31:317-30
   PubMed Web of Science ®Google Scholar
• Katz SL, Enders JF, Holloway A. The development and evaluation of an attenuated measles virus vaccine. Am J Public Health Nations Health 1962;52(Suppl):5-10
   PubMed Web of Science ®Google Scholar
• Perry RT, Gacic-Dobo M, Dabbagh A, et al. Global control and regional elimination of measles, 2000-2012. MMWR Morb Mortal Wkly Rep 2014;63:103-7
   PubMed Web of Science ®Google Scholar
• Moss WJ, Griffin DE. Measles. Lancet 2012;379:153-64
   PubMed Web of Science ®Google Scholar
• Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 2012;379:2173-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Increased transmission and outbreaks of measles - European region, 2011. MMWR Morb Mortal Wkly Rep 2012;60:1605-10
   Google Scholar
• Strebel PM, Cochi S, Hoekstra E, et al. A world without measles. J Infect Dis 2011;204:S1-3
   PubMed Web of Science ®Google Scholar
• Melnick JL. Thermostability of poliovirus and measles vaccines. Dev Biol Stand 1996;87:155-60
   PubMedGoogle Scholar
• Simonsen L, Kane A, Lloyd J, et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999;77:789-800
   PubMed Web of Science ®Google Scholar
• Halsey NA, Boulos R, Mode F, et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985;313:544-9
   PubMed Web of Science ®Google Scholar
• Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977;91:715-18
   PubMed Web of Science ®Google Scholar
• Higginson D, Theodoratou E, Nair H, et al. An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children. BMC Public Health 2011;11(Suppl 3):S31
   PubMed Web of Science ®Google Scholar
• Sabin AB. Immunization against measles by aerosol. Rev Infect Dis 1983;5:514-23
   PubMedGoogle Scholar
• Sabin AB, Flores Arechiga A, Fernandez de Castro J, et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983;249:2651-62
   PubMed Web of Science ®Google Scholar
• Sabin AB, Fernandez de Castro J, Flores Arechiga A, et al. Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet 1982;2:604
   PubMed Web of Science ®Google Scholar
• Sabin AB, Flores Arechiga A, Fernandez de Castro J, et al. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984;251:2363-71
   PubMed Web of Science ®Google Scholar
• Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 1997;25:323-38
   PubMed Web of Science ®Google Scholar
• LiCalsi C, Maniaci MJ, Christensen T, et al. A powder formulation of measles vaccine for aerosol delivery. Vaccine 2001;19:2629-36
   PubMed Web of Science ®Google Scholar
• Burger JL, Cape SP, Braun CS, et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 2008;21:25-34
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Bauch CT, Bresnahan BW, et al. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. J Infect Dis 2011;204(Suppl 1):S124-32
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the strategic advisory group of expers on immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2013;88:1-16
   PubMedGoogle Scholar
• Black FL, Sheridan SR. Studies on an attenuated measles virus vaccine IV. Administration of vaccine by several routes. N Engl J Med 1960;263:165-9
   PubMed Web of Science ®Google Scholar
• Okuno Y. Vaccination with egg passage measles virus by inhalation. Am J Dis Child 1962;103:381-4
   PubMedGoogle Scholar
• Sabin AB. My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics 1992;90:162-9
   PubMed Web of Science ®Google Scholar
• Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 2007;25:4170-4
   PubMed Web of Science ®Google Scholar
• Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 2000;355:798-803
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Islas-Romero R, García-García Mde L, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 2006;24:683-90
   PubMed Web of Science ®Google Scholar
• Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-7
   PubMed Web of Science ®Google Scholar
• Muhlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480:530-3
   PubMed Web of Science ®Google Scholar
• Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 2011;7:e1002240
   PubMed Web of Science ®Google Scholar
• Lemon K, de Vries RD, Mesman AW, et al. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog 2011;7:e1001263
   PubMed Web of Science ®Google Scholar
• de Vries RD, Lemon K, Ludlow M, et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 2010;84:4714-24
   PubMed Web of Science ®Google Scholar
• de Swart RL, Ludlow M, de Witte L, et al. Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 2007;3:e178
   Web of Science ®Google Scholar
• Mesman AW, de Vries RD, McQuaid S, et al. A prominent role for DC-SIGN+ dendritic cells in initiation and dissemination of measles virus infection in non-human primates. PLoS One 2012;7:e49573
   Web of Science ®Google Scholar
• Ludlow M, Rennick LJ, Sarlang S, et al. Wild-type measles virus infection of primary epithelial cells occurs via the basolateral surface without syncytium formation or release of infectious virus. J Gen Virol 2010;91:971-9
   PubMed Web of Science ®Google Scholar
• Racaniello V. An exit strategy for measles virus. Science 2011;334:1650-1
   PubMed Web of Science ®Google Scholar
• Leonard VH, Sinn PL, Hodge G, et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008;118:2448-58
   PubMed Web of Science ®Google Scholar
• Ludlow M, Lemon K, de Vries RD, et al. Measles virus infection of epithelial cells in the macaque upper respiratory tract is mediated by subepithelial immune cells. J Virol 2013;87:4033-42
   PubMed Web of Science ®Google Scholar
• Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295-305
   PubMed Web of Science ®Google Scholar
• Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993;67:6025-32
   PubMed Web of Science ®Google Scholar
• Simon JK, Ramirez K, Cuberos L, et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin Vaccine Immunol 2011;18:355-61
   PubMedGoogle Scholar
• Coates AL, Dinh L, MacNeish CF, et al. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000;13:169-78
   PubMedGoogle Scholar
• Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983;38:755-9
   PubMed Web of Science ®Google Scholar
• Sullivan VJ, Mikszta JA, Laurent P, et al. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv 2006;3:87-95
   PubMedGoogle Scholar
• Zilliox MJ, Moss WJ, Griffin DE. Gene expression changes in peripheral blood mononuclear cells during measles virus infection. Clin Vaccine Immunol 2007;14:918-23
   PubMed Web of Science ®Google Scholar
• Shivakoti R, Siwek M, Hauer D, et al. Induction of dendritic cell production of type I and type III interferons by wild-type and vaccine strains of measles virus: role of defective interfering RNAs. J Virol 2013;87:7816-27
   PubMed Web of Science ®Google Scholar
• Cohen BJ, Audet S, Andrews N, et al. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007;26:59-66
   PubMed Web of Science ®Google Scholar
• Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990;162:1036-42
   PubMed Web of Science ®Google Scholar
• Nair N, Moss WJ, Scott S, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009;200:1031-8
   PubMed Web of Science ®Google Scholar
• Moss WJ, Ryon JJ, Monze M, Griffin DE. Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis 2002;186:879-87
   PubMed Web of Science ®Google Scholar
• Lin WH, Vilalta A, Adams RJ, et al. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins. J Virol 2013;87:6560-8
   Google Scholar
• Permar SR, Klumpp SA, Mansfield KG, et al. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003;77:4396-400
   PubMed Web of Science ®Google Scholar
• Jaye A, Herberts CA, Jallow S, et al. Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles. J Virol 2003;77:5014-16
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Islas-Romero R, García-García Mde L, et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 2004;189:254-7
   PubMed Web of Science ®Google Scholar
• Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 2002;80:806-12
   PubMed Web of Science ®Google Scholar
• Coates AL, Tipples G, Leung K, et al. How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine 2006;24:1578-85
   PubMed Web of Science ®Google Scholar
• de Swart RL, Kuiken T, Fernandez-de Castro J, et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 2006;24:6424-36
   PubMed Web of Science ®Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda D, et al. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine 2010;28:692-8
   PubMed Web of Science ®Google Scholar
• Bellanti JA, Zeligs BJ, Mendez-Inocencio J, et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 2004;22:1214-20
   PubMed Web of Science ®Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda D, et al. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine 2010;28:7228-32
   PubMed Web of Science ®Google Scholar
• Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008;26:383-98
   PubMed Web of Science ®Google Scholar
• Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin 2005;1:30-6
   PubMed Web of Science ®Google Scholar
• Sabin AB, Albrecht P, Takeda AK, et al. High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis 1985;152:1231-7
   PubMed Web of Science ®Google Scholar
• Khanum S, Uddin N, Garelick H, et al. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1987;1:150-3
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Garcia-Leon ML, Espinosa-Torres Torrija B, et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J Infect Dis 2011;204:426-32
   PubMed Web of Science ®Google Scholar
• de Swart RL, LiCalsi C, Quirk AV, et al. Measles vaccination of macaques by dry powder inhalation. Vaccine 2007;25:1183-90
   PubMed Web of Science ®Google Scholar
• Sievers RE, Quinn BP, Cape SP, et al. Near-critical fluid micronization of stabilized vaccines, antibiotics and anti-virals. J Supercritical Fluids 2007;42:385-91
   Web of Science ®Google Scholar
• Cape SP, Villa JA, Huang ET, et al. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 2008;25:1967-90
   PubMed Web of Science ®Google Scholar
• Kisich KO, Higgins MP, Park I, et al. Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation. Vaccine 2011;29:905-12
   PubMed Web of Science ®Google Scholar
• Huang J, Mikszta JA, Ferriter MS, et al. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccin 2007;3:90-3
   PubMed Web of Science ®Google Scholar
• Huang J, D’Souza AJ, Alarcon JB, et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol 2009;16:719-25
   PubMed Web of Science ®Google Scholar
• Lin WH, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci USA 2011;108:2987-92
   PubMed Web of Science ®Google Scholar
• Scott P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis 2011;204(Suppl 1):S164-78
   PubMedGoogle Scholar
• Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998;129:104-6
   PubMed Web of Science ®Google Scholar
• Song K, Bolton DL, Wei CJ, et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci USA 2010;107:22213-18
   PubMed Web of Science ®Google Scholar
• Corbett M, Bogers WM, Heeney JL, et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 2008;105:2046-51
   PubMed Web of Science ®Google Scholar
• Shibeshi ME, Masresha BG, Smit SB, et al. Measles resurgence in southern Africa: challenges to measles elimination. Vaccine 2014;32(16):1798-807
   PubMed Web of Science ®Google Scholar
• Cutts FT, Lessler J, Metcalf CJ. Measles elimination: progress, challenges and implications for rubella control. Expert Rev Vaccines 2013;12:917-32
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rubella and congenital rubella syndrome control and elimination - global progress, 2000-2012. MMWR Morb Mortal Wkly Rep 2013;62:983-6
   PubMed Web of Science ®Google Scholar